VIE News and Press, Viela Bio Inc. From 03/03/22

Veolia North America, DuPont Partnership Achieves Significant Reductions in Greenhouse Gas Emissions Conversion from coal to natural gas results in more than 200,000 tons in GHG reductions at DuPont's largest manufacturing facility PR Newswire BOSTON , March 3,...

TAL’s decision to end the tutoring services to students from kindergarten through ninth grade (K9 Academic AST Services) is likely to disrupt its business operations in 2022. TAL's net income has grown 21.82% from 2017 to $334.4 million in May 2021 but declined 19% in the year ...

janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...

Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...

Merger activity remained steady last week. Two of the largest deals of this year were announced last week. SPAC activity continues to grow at a steady pace. For further details see: Merger Arbitrage Mondays - Coherent Shareholders Delighted By Another Round Of Counteroff...

Horizon Therapeutics (HZNP) announces that it has completed the acquisition of Viela Bio (VIE), a deal that valued the company at $3.05B.Horizon expects the deal to reduce its adjusted EBITDA by about $140M in 2021, nearly all of which is attributable to increased R&D investment.Horizon s...

Horizon will acquire Viela Bio for $53 per share or $3.05 billion. The acquisition brings a marketed product Uplizna and three additional pipeline candidates. The acquisition also brings significant upside optionality for Horizon as it broadens the pipeline and looks like a good f...

VIELA BIO (VIE): FY GAAP EPS of -$2.83 beats by $0.12.Revenue of $11.65M (-76.7% Y/Y) beats by $3.72M.As of Dec. 31, 2020, Viela had $378.5M in cash, cash equivalents, and marketable securities and no outstanding debt.Press Release For further details see: VIELA BIO EPS beats by $0.12, ...

GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported financial resu...

-No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with previous exposure to off-label therapy- GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE N...